![]() |
|
Identifiers | |
---|---|
|
|
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C23H31ClN4O3S |
Molar mass | 479.03524 g/mol |
3D model (JSmol) | |
|
|
|
SR9011 is a research drug that was developed by Professor Thomas Burris of Scripps as an agonist of Rev-ErbAα with a half-maximum inhibitory concentration (IC50) = 790 nM for Rev-Erbα and IC50 = 560 nM for Rev-ErbAβ.